API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG).
Lead Product(s): Cretostimogene Grenadenorepvec,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022